about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

FDA clears 3rd shot of mR­NA Covid-19 vac­cines for the im­muno­com­pro­mised

4 years ago
FDA+
Coronavirus

Aprea dis­clos­es sec­ond clin­i­cal hold in a week, this time for lym­phoma study

4 years ago
FDA+

Covid-19 roundup: OCD drug shows 31% hos­pi­tal­iza­tion re­duc­tion in plat­form tri­al; EUA for boost­er mR­NA shot im­mi­nent ...

4 years ago
Coronavirus

Pur­due sub­sidiary nabs non-opi­oid drug for pain; Or­biMed backs small biotech's 'su­pe­ri­or' drug

4 years ago
News Briefing

The Car­lyle Group ax­es auc­tion by call­ing its $1.3B bid for Vec­tura 'fi­nal' — now the ball is in Philip Mor­ris' ...

4 years ago
Deals

Keytru­da keeps ex­pand­ing with an­oth­er pri­or­i­ty re­view; Medicxi-backed eye drop mak­er wins new fund­ing, re­gion­al deal

4 years ago
News Briefing

BioN­Tech ex­pects to be $18.6B rich­er af­ter this year as Covid boost­ers churn out more da­ta. But it won't change much

4 years ago
Pharma
Coronavirus

ADC ex­perts at Seagen find a $2.6B HER2 gem in Chi­na that they think can go where En­her­tu, Kad­cy­la can't

4 years ago
Deals
China

Robert Baze­more inks one last deal for Epizyme — adding Chi­na to Tazverik's glob­al blue­print — be­fore head­ing out ...

4 years ago
Deals
China

Biotech grieves over Tachi’s pass­ing; $3 tril­lion mi­rage?; Sanofi has a new Pompe drug; and more

4 years ago
Weekly

FDA or­ders clin­i­cal hold on Aprea's p53 re­ac­ti­va­tor as strug­gling biotech pledges to ad­dress safe­ty con­cerns

4 years ago
FDA+

A small vac­cine de­vel­op­er fa­vored by the UK gov­ern­ment in Covid-19 touts a PhI­II first in chikun­gun­ya

4 years ago
R&D

Soft­Bank claims $5B stake in Roche amid grand plans to in­vest in biotech — re­ports

4 years ago
Deals

Am­gen halts a PhI for FLT3 BiTE while re­sum­ing dos­ing on an­oth­er

4 years ago
R&D

Roche's PD-L1 fran­chise play­er nabs pri­or­i­ty re­view; One of world's first psy­che­delics re­search in­sti­tutes opens in ...

4 years ago
News Briefing

Sage drops a pair of late-stage tests for Bio­gen-part­nered de­pres­sion drug, rais­ing the stakes on a fi­nal tri­al

4 years ago
R&D

FDA lifts year-plus hold on No­var­tis' Zol­gens­ma, set­ting the stage for new PhI­II

4 years ago
Cell/Gene Tx
FDA+

With clin­i­cal tri­als lined up for Zen­tal­is drugs, Chi­na's Zen­tera sets its sights on more deal­mak­ing and an IPO

4 years ago
Financing
China

Watch out Glax­o­SmithK­line: As­traZeneca's once-failed lu­pus drug is now ap­proved

4 years ago
FDA+

Not all mR­NA vac­cines are cre­at­ed equal. Does it mat­ter?; Neu­ro is back; Pri­vate M&A af­fair; and more

4 years ago
Weekly

On the heels of Take­da pact, Pep­tiDream kicks off $2.2B deal to broad­en Al­ny­lam's siR­NA de­liv­ery scope

4 years ago
Deals

Shoot­ing straight for Ven­clex­ta, a sea­soned Chi­nese CEO has glob­al dreams for his start­up

4 years ago
Financing
China

Roche nabs pri­or­i­ty re­view for Eylea com­peti­tor; Italy's An­geli­ni eyes CNS, rare dis­ease star­tups with $35M Lu­mi­ra ...

4 years ago
News Briefing

As lead­ing syn­bio play­ers bask in spot­light, US/Chi­na start­up lands $100M to find its own niche

4 years ago
Financing
First page Previous page 46474849505152 Next page Last page
A service from the Financial Times